ProMetic Life Sciences Inc.


in

ProMetic Life Sciences Inc. has signed the definitive agreement for development of two hyperimmunes with Kedrion S.p.A. The first product to be developed will target the Hepatitis B Hyperimmune market which is currently estimated in Europe and in the U.S. to be at $200 million and is expected to be at $400 million by 2015. Kedrion will provide an upfront and milestone payments, as well as service fees to ProMetic amounting to $2 million over the next twelve months.